Q&A Interview with CEO of Visualant, Inc. (OTCBB: VSUL) Discussing Breakthrough Sensor Technology
Point Roberts, WA - July19, 2011 - Investorideas.com, an investor research portal covering multiple stock sectors including defense and security stocks, presents a Q&A interview with Ronald Erickson, CEO of Visualant, Inc. (OTCBB: VSUL).
Mr. Erickson discusses the ability of Visualant's sensor technology, a patent-pending technology that utilizes controlled illumination with specific bands of light, to create a unique spectral signature.
Q: Investorideas.com
Ron, can you explain to investors how yourSpectral Pattern Matching technology works?
A: Ronald Erickson, CEO, President
We map color at the photon level with our proprietary scanner. We use our proprietary algorithms to place that mapping in a database. We then use that information, with our scanner to authenticate or diagnose based upon color.
Q: Investorideas.com
Your primary focus is the security and Homeland Security market, but you continue to expand into new applications and markets. Can you give investors insight as to the new opportunities in front of you and what that represents for the company moving forward?
A: Ronald Erickson, CEO, President
Early this year we licensed Visualant technology to Javelin LLC, a Seattle based technology company, for the limited purpose of focusing upon environmental applications of our Spectral Pattern Matching technology. We believe there are profound applications of our technology in not only the environmental arena, but also in forensic science, medical and agricultural diagnostics as well.
Q: Investorideas.com
One of the applications for the technology, I read on your website, includes the ability to help define and diagnose disease. Can you tell us more about that?
A: Ronald Erickson, CEO, President
To make the point that our technology can play a role in defining and diagnosing disease I often say to people, “Have you ever said, ‘You don't look well.'” When you say that, you are making a judgment based upon visual cues, including color. Disease is not static. Color changes during a disease process. Interestingly, there are 2000 year old Chinese texts that speak of using color as a diagnostic. We believe there are numerous medical diagnostic applications for our SPM technology.
Q: Investorideas.com
How does your technology compare to other competitive technologies in the market?
A: Ronald Erickson, CEO, President
We don't see any directly competitive technology in the marketplace today. Spectrometers are competitive, but they are very expensive and fragile. We believe we have an advantage both in terms of utility and price point and see no direct competitors today.
Q: Investorideas.com
Ron, with all of the multiple applications and uses for your technology, is your roll out plan to still attract partners for each application? And if so, how is that developing?
A: Ronald Erickson, CEO, President
We will focus our efforts on security and authentication applications. In other fields of use such as medical, for example, we will seek out the best partners. We are in discussions with a number of partners in several fields of use. You can expect to see announcements regarding those relationships over time.
About Visualant, Inc. (OTCBB: VSUL)
Visit the company profile on Investorideas.com
http://www.investorideas.com/CO/VSUL/
Visualant, Inc. develops low-cost, high speed, light-based security and quality control solutions for use in homeland security, anti-counterfeiting, forgery/fraud prevention, brand protection and process control applications. Its patent-pending technology uses controlled illumination with specific bands of light, to establish a unique spectral signature for both individual and classes of items. When matched against existing databases, these spectral signatures allow precise identification and authentication of any item or substance. This breakthrough optical sensing and data capture technology is called Spectral Pattern Matching (SPM). SPM technology can be miniaturized and is easily integrated into a variety of hand-held or fixed mount configurations, and can be combined in the same package as a bar-code or biometric scanner. www.visulant.net
Through its wholly owned subsidiary, TransTech Systems, Inc., the Company provides security and authentication solutions to security and law enforcement markets throughout the United States. www.ttsys.com
Contact Visualant, Inc.
Lynn Felsinger, 206-903-1341
lynn@visualant.net
Investor Relations Core Consulting Group
Paul DeRiso, 925-465-6088
paul@coreconsultingroup.com
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Defense and security portals:
www.HomelandDefenseStocks.com and www.nationalhomelandsecurityknowledgebase.com
Request news and trading alerts on VSUL and other defense stocks
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer:
T his news is paid for as part of the showcase advertising program for Visualant, Inc. (OTCBB: VSUL) Visualant is a featured showcase company on Investorideas.com, 1500 per month and $five thousand per month in restricted 144 shares. Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All information on showcase companies is taken from public documents, news, filings and the company website and management. This site is currently compensated by featured companies, news submissions and online advertising. Investors are reminded all investment involves risk including possible loss of principal.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Contact Investorideas.com
dvanzant@investorideas.com 800 665 0411
Visualant, Inc. (OTCBB:VSUL) Featured showcase company on Investorideas.com and related security portals and blogs
Visit the showcase page: http://www.investorideas.com/CO/VSUL/
Disclosure and Disclaimer: Visualant, Inc. (OTCBB:VSUL) is a paid advertising featured showcase company on Investorideas.com and related security portals and blogs.
(1500 per month and $five thousand per month in restricted 144 shares)
Tuesday, July 19, 2011
Gold and Mining Stock Alert; TurkPower (OTCBB: TRKP) Closes up 21%
Point Roberts WA - July 19, 2011 (Investorideas.com Mining Newswire) - www.Investorideas.com, a leader in sector research for investors including mining and resource stocks, issues a technical trading alert for iron ore stock, TurkPower Corporation (OTCBB:TRKP). The stock closed trading July 18 th at $0.34, up 0.06 (21.43%).
Recent News: TurkPower Corporation (OTC.BB: TRKP) to Acquire Majority Interest in Operational Iron Ore Mine in Turkey
http://www.investorideas.com/CO/TRKP/news/2011/07051.asp
TurkPower Corporation (OTCBB:TRKP) is a Turkish-American junior mining company that is acquiring controlling ownership in an operational iron ore mine and several mining projects under development in Turkey. TurkPower's sole focus is on the booming Turkish mining industry, where it aims to become a leader in developing, operating and owning base metal mines by acquiring and consolidating operational mines with proven reserves, utilizing economies of scale to increase returns as well as developing new mining assets. TurkPower's board of directors, management team and employees have extensive experience and relations in the Turkish mining industry, as well as ongoing relations with the relevant government agencies, allowing TurkPower to participate in the major opportunities currently developing in Turkey.
Visit the company profile at Investorideas.com
http://www.investorideas.com/CO/TRKP/
Sign up for news on TRKP and other mining stocks
http://www.investorideas.com/Resources/Newsletter.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sectors. Sectors we cover include; water stocks, gold and mining stocks, China stocks, oil and gas stocks, renewable energy stocks, coal stocks, tech stocks, biotech stocks, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer/ Disclosure: The following news is paid for and /or published as information only for our readers. TRKP is a paid advertising client ( three thousand five hundred per month, 150,000 144 shares) Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of principal .This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
For Additional Information about Investorideas.com energy portals: 800-665-0411 or cvanzant@investorideas.com
Point Roberts WA - July 19, 2011 (Investorideas.com Mining Newswire) - www.Investorideas.com, a leader in sector research for investors including mining and resource stocks, issues a technical trading alert for iron ore stock, TurkPower Corporation (OTCBB:TRKP). The stock closed trading July 18 th at $0.34, up 0.06 (21.43%).
Recent News: TurkPower Corporation (OTC.BB: TRKP) to Acquire Majority Interest in Operational Iron Ore Mine in Turkeyhttp://www.investorideas.com/CO/TRKP/news/2011/07051.asp
TurkPower Corporation (OTCBB:TRKP) is a Turkish-American junior mining company that is acquiring controlling ownership in an operational iron ore mine and several mining projects under development in Turkey. TurkPower's sole focus is on the booming Turkish mining industry, where it aims to become a leader in developing, operating and owning base metal mines by acquiring and consolidating operational mines with proven reserves, utilizing economies of scale to increase returns as well as developing new mining assets. TurkPower's board of directors, management team and employees have extensive experience and relations in the Turkish mining industry, as well as ongoing relations with the relevant government agencies, allowing TurkPower to participate in the major opportunities currently developing in Turkey.
Visit the company profile at Investorideas.com
http://www.investorideas.com/CO/TRKP/
Sign up for news on TRKP and other mining stocks
http://www.investorideas.com/Resources/Newsletter.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sectors. Sectors we cover include; water stocks, gold and mining stocks, China stocks, oil and gas stocks, renewable energy stocks, coal stocks, tech stocks, biotech stocks, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer/ Disclosure: The following news is paid for and /or published as information only for our readers. TRKP is a paid advertising client ( three thousand five hundred per month, 150,000 144 shares) Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of principal .This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
For Additional Information about Investorideas.com energy portals: 800-665-0411 or cvanzant@investorideas.com
TurkPower Corporation (OTC.BB: TRKP) is a showcase mining stock on Investorideas.com
Visit the showcase profile for TurkPower Corporation (OTC.BB: TRKP) to learn more about the company
Request News alerts for TurkPower Corporation (OTC.BB: TRKP)
Disclosure: Investorideas.com is compensated by TurkPower Corporation: (OTC.BB:TRKP) May 18 2011 (6 months- 3500 per month 150,000 144 shares)
Visit the showcase profile for TurkPower Corporation (OTC.BB: TRKP) to learn more about the company
Request News alerts for TurkPower Corporation (OTC.BB: TRKP)
Monday, July 18, 2011
NASDAQ Morning Top Percentage Gainers July 18th: HEV, JVA, SCEI, PPDI
POINT ROBERTS, July 18, 2011 - www.InvestorIdeas.com, a global investor research portal for independent investors, reports on top percentage gainers on the NASDAQ in morning trading for July 18, 2011.Ener1, Inc., Inc topped the gainer list, rising about 20.34% at the time of this report.
Ener1, Inc. (NASDAQ:HEV) soared 0.160 (20.34%) to $0.949 following news Ener1, Inc. and Wanxiang Electric Vehicle Co., Ltd., a division of the Chinese conglomerate Wanxiang Group Corporation have received approval from the Chinese government for their joint venture to co-manufacture lithium-ion energy storage systems for the China market.
Coffee Holding Co., Inc. (NASDAQ:JVA) also rose 1.43 (7.23%) to $21.22 after slumping 28% last week. The stock has jumped 472% so far this year. It has a 52-week range of $3.67-$30.98. The company has a market capitalization of $116.68 million.
Sino Clean Energy Inc. (NASDAQ:SCEI) climbed 0.42 (20.69%) to $2.43 after it has entered into a non-binding, preliminary agreement to acquire 100% stake in Crown Energy Limited, an investment company registered in Hong Kong, which as its sole business holds a 60% stake in Foshan Nan Hai CWSF Co., Ltd. ("Foshan Nan Hai"). If after due diligence the Company decides to complete the acquisition, Sino Clean Energy will control a 60% stake in Foshan Nan Hai, a producer and distributor of CWSF in China.
Pharmaceutical Product Development, Inc. (NASDAQ:PPDI) surged 3.41 (12.24%) to $31.25 after the Wall Street Journal reported, that the company is considering selling itself and added the company could receive bids from private equity and larger clinical-research providers, although PPD could still alter its plans.
Investorideas.com Free Investor Tools;
Sign up for the free investor news and stock alerts in leading sectors! http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas - Research energy stocks, mining, agriculture stocks, cloud computing stocks and more…
Investorideas.com Members currently have 24/7 online access to the exclusive subscriber-only eleven stock directories in leading sectors including renewable energy, water and energy stocks.
Visit the Investor Ideas membership page to learn more at: http://www.investorideas.com/membership/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising . www.InvestorIdeas.com/About/Disclaimer.asp
For Additional Information and or interest in becoming a content /revenue partner:
Dawn Van Zant: 800-665-0411 - dvanzant@investorideas.com
Source - Investorideas.com
POINT ROBERTS, July 18, 2011 - www.InvestorIdeas.com, a global investor research portal for independent investors, reports on top percentage gainers on the NASDAQ in morning trading for July 18, 2011.Ener1, Inc., Inc topped the gainer list, rising about 20.34% at the time of this report.
Ener1, Inc. (NASDAQ:HEV) soared 0.160 (20.34%) to $0.949 following news Ener1, Inc. and Wanxiang Electric Vehicle Co., Ltd., a division of the Chinese conglomerate Wanxiang Group Corporation have received approval from the Chinese government for their joint venture to co-manufacture lithium-ion energy storage systems for the China market.
Coffee Holding Co., Inc. (NASDAQ:JVA) also rose 1.43 (7.23%) to $21.22 after slumping 28% last week. The stock has jumped 472% so far this year. It has a 52-week range of $3.67-$30.98. The company has a market capitalization of $116.68 million.
Sino Clean Energy Inc. (NASDAQ:SCEI) climbed 0.42 (20.69%) to $2.43 after it has entered into a non-binding, preliminary agreement to acquire 100% stake in Crown Energy Limited, an investment company registered in Hong Kong, which as its sole business holds a 60% stake in Foshan Nan Hai CWSF Co., Ltd. ("Foshan Nan Hai"). If after due diligence the Company decides to complete the acquisition, Sino Clean Energy will control a 60% stake in Foshan Nan Hai, a producer and distributor of CWSF in China.
Pharmaceutical Product Development, Inc. (NASDAQ:PPDI) surged 3.41 (12.24%) to $31.25 after the Wall Street Journal reported, that the company is considering selling itself and added the company could receive bids from private equity and larger clinical-research providers, although PPD could still alter its plans.
Investorideas.com Free Investor Tools;
Sign up for the free investor news and stock alerts in leading sectors! http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas - Research energy stocks, mining, agriculture stocks, cloud computing stocks and more…
Investorideas.com Members currently have 24/7 online access to the exclusive subscriber-only eleven stock directories in leading sectors including renewable energy, water and energy stocks.
Visit the Investor Ideas membership page to learn more at: http://www.investorideas.com/membership/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising . www.InvestorIdeas.com/About/Disclaimer.asp
For Additional Information and or interest in becoming a content /revenue partner:
Dawn Van Zant: 800-665-0411 - dvanzant@investorideas.com
Source - Investorideas.com
Retail/Consumer Investor Trading Alert; YesDTC Holdings, Inc. (OTCBB: YESD) Soars on News of MotorBooster Engine Catalyst Fuel Saving Technology
July 18, 2011 (Investorideas.com newswire) - Investorideas.com, a leader in sector research for investors reports that YesDTC Holdings, Inc. (OTCBB:YESD) had sharp gains in early trading, up over 100% following news on its MotorBooster Engine Catalyst fuel- saving technology being tested by a major oil company.
Major Oil Company to Support Comprehensive Test of YesDTC's (OTCBB: YESD) MotorBooster Engine Catalyst Product - Product Already Showing 16.5% Fuel Savings
SAN FRANCISCO - July 18, 2011 (Investorideas.com newswire) - YesDTC Holdings, Inc. (OTCBB:YESD), a direct-to-consumer marketer and global distributor of consumer goods and products, today announced another significant development involving the recently announced performance test of its MotorBooster(TM) fuel catalyst formulation being conducted by the University of Alaska, Fairbanks (UAF). In addition to tests by the UAF, a major Alaskan oil exploration company has also expressed significant interest in the testing protocol and has stated its intent, assuming favorable test results of MotorBooster by the UAF, to employ one or more of the products across its entire fleet.
Read today's full news:
http://www.investorideas.com/CO/YESD/news/2011/07181.asp
About YesDTC Holdings, Inc. (OTCBB: YESD)
YesDTC Holdings, Inc. is a direct-to-consumer marketing company specializing in direct response television (DRTV), Internet and retail marketing programs. The Company brings a unique set of skills to this market space. YesDTC combines both the creative talents and financial acumen needed to create a total package for direct-to-consumer marketing programs. Importantly, the Company also maintains a strategic partnership with Schulberg Media Works (SMW), a pioneering media production firm in the direct-to-consumer space with a highly acclaimed list of successful client campaigns and product infomercials. The Company's infomercial for its MediPendant product can be seen at www.medipendant.com. Information on NutriFusion can be seen at www.nutrifusion.com and information about the Company's newest offering from Alo Networks can be found at http://www.alonetworks.com/. More information on YesDTC Holdings can be found at www.yesdtc.com.
Learn more about YESD at Investorideas.com
http://www.investorideas.com/CO/YESD/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising .
Disclosure, Disclaimer YESD is a paid advertising client on Investorideas and Investorideas.com owns shares in the company
www.InvestorIdeas.com/About/Disclaimer.asp
Contact Investorideas.com
800 665 0411
cvanzant@investorideas.com
Contact Investorideas.com
dvanzant@investorideas.com
Visit the YESD showcase profile at Investorideas.com
http://www.investorideas.com/CO/YESD/
Request News and Info on YESD
Disclosure, Disclaimer/ YESD is a paid advertising client on Investorideas.com.
YESD: one time fee of five thousand cash and three hundred thousand 144 shares
About Investorideas.com
- Investor Ideas the can change the world
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics
Investor Protection and Regulation for Pinks sheets: http://www.pinksheets.com/otcguide/investors_protection.jsp
July 18, 2011 (Investorideas.com newswire) - Investorideas.com, a leader in sector research for investors reports that YesDTC Holdings, Inc. (OTCBB:YESD) had sharp gains in early trading, up over 100% following news on its MotorBooster Engine Catalyst fuel- saving technology being tested by a major oil company.
Major Oil Company to Support Comprehensive Test of YesDTC's (OTCBB: YESD) MotorBooster Engine Catalyst Product - Product Already Showing 16.5% Fuel Savings
SAN FRANCISCO - July 18, 2011 (Investorideas.com newswire) - YesDTC Holdings, Inc. (OTCBB:YESD), a direct-to-consumer marketer and global distributor of consumer goods and products, today announced another significant development involving the recently announced performance test of its MotorBooster(TM) fuel catalyst formulation being conducted by the University of Alaska, Fairbanks (UAF). In addition to tests by the UAF, a major Alaskan oil exploration company has also expressed significant interest in the testing protocol and has stated its intent, assuming favorable test results of MotorBooster by the UAF, to employ one or more of the products across its entire fleet.
Read today's full news:
http://www.investorideas.com/CO/YESD/news/2011/07181.asp
About YesDTC Holdings, Inc. (OTCBB: YESD)
YesDTC Holdings, Inc. is a direct-to-consumer marketing company specializing in direct response television (DRTV), Internet and retail marketing programs. The Company brings a unique set of skills to this market space. YesDTC combines both the creative talents and financial acumen needed to create a total package for direct-to-consumer marketing programs. Importantly, the Company also maintains a strategic partnership with Schulberg Media Works (SMW), a pioneering media production firm in the direct-to-consumer space with a highly acclaimed list of successful client campaigns and product infomercials. The Company's infomercial for its MediPendant product can be seen at www.medipendant.com. Information on NutriFusion can be seen at www.nutrifusion.com and information about the Company's newest offering from Alo Networks can be found at http://www.alonetworks.com/. More information on YesDTC Holdings can be found at www.yesdtc.com.
Learn more about YESD at Investorideas.com http://www.investorideas.com/CO/YESD/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising .
Disclosure, Disclaimer YESD is a paid advertising client on Investorideas and Investorideas.com owns shares in the company
www.InvestorIdeas.com/About/Disclaimer.asp
Contact Investorideas.com
800 665 0411
cvanzant@investorideas.com
Contact Investorideas.com
dvanzant@investorideas.com
Visit the YESD showcase profile at Investorideas.com
http://www.investorideas.com/CO/YESD/
Request News and Info on YESD
Disclosure, Disclaimer/ YESD is a paid advertising client on Investorideas.com.
YESD: one time fee of five thousand cash and three hundred thousand 144 shares
About Investorideas.com
- Investor Ideas the can change the world
Sign up for free stock alerts and news:
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.http://www.investorideas.com/Resources/Newsletter.asp
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics
Investor Protection and Regulation for Pinks sheets: http://www.pinksheets.com/otcguide/investors_protection.jsp
Energy Stock News Alert; (OTCBB: AAPH) Plans Drilling at North Oklahoma Project
July 18, 2011 (Investorideas.com energy newswire) - Investorideas.com, a leader in sector research for investors reports junior oil and gas company, American Petro-Hunter, Inc. (OTC.BB:AAPH) updated plans regarding the Company's continued participation in a proposed field development horizontal drilling program of the Mississippi formation at the North Oklahoma Project.
Based on the commercial success of the recent NOM-1H horizontal well, the Company and working interest partners have determined that the development plan for this newly defined Mississippi oil and gas reservoir can accommodate the drilling of a minimum of 11 horizontal wells.
Read today's news:
http://www.investorideas.com/CO/AAPH/ news/2011/07181.asp
About American Petro-Hunter, Inc. (OTCBB: AAPH)
The Company is a goal-oriented exploration and production (E&P) Company aiming to become an intermediate level oil and gas producer within 12 months. The Company is in production at the Poston Project in Trego County Kansas with new drilling activity and production underway at the North Oklahoma Oil Project. With the achievable target of becoming a 1000 BOE producer as our goal, American Petro-Hunter is actively on the "hunt" for domestic petroleum assets. Visit us at: www.americanpetrohunter.com
Learn more about AAPH at Investorideas.com:
http://www.investorideas.com/CO/AAPH/
Contact the company
Contact:
Investor Relations:
Mountainview IR Services, Inc.
1-888-521-7762
investors@americanpetrohunterinc.com
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising .
Disclosure, Disclaimer/ AAPH is a paid advertising client on Investorideas.com.
American Petro-hunter Inc. (AAPH.OB) showcase energy stock on Investorideas.com and energy portals and blogs (averages two thousand per month)
www.InvestorIdeas.com/About/Disclaimer.asp
Contact Investorideas.com
800 665 0411
cvanzant@investorideas.com
July 18, 2011 (Investorideas.com energy newswire) - Investorideas.com, a leader in sector research for investors reports junior oil and gas company, American Petro-Hunter, Inc. (OTC.BB:AAPH) updated plans regarding the Company's continued participation in a proposed field development horizontal drilling program of the Mississippi formation at the North Oklahoma Project.
Based on the commercial success of the recent NOM-1H horizontal well, the Company and working interest partners have determined that the development plan for this newly defined Mississippi oil and gas reservoir can accommodate the drilling of a minimum of 11 horizontal wells.
Read today's news:
http://www.investorideas.com/CO/AAPH/ news/2011/07181.asp
About American Petro-Hunter, Inc. (OTCBB: AAPH)
The Company is a goal-oriented exploration and production (E&P) Company aiming to become an intermediate level oil and gas producer within 12 months. The Company is in production at the Poston Project in Trego County Kansas with new drilling activity and production underway at the North Oklahoma Oil Project. With the achievable target of becoming a 1000 BOE producer as our goal, American Petro-Hunter is actively on the "hunt" for domestic petroleum assets. Visit us at: www.americanpetrohunter.com
Learn more about AAPH at Investorideas.com: http://www.investorideas.com/CO/AAPH/
Contact the company
Contact:
Investor Relations:
Mountainview IR Services, Inc.
1-888-521-7762
investors@americanpetrohunterinc.com
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising .
Disclosure, Disclaimer/ AAPH is a paid advertising client on Investorideas.com.
American Petro-hunter Inc. (AAPH.OB) showcase energy stock on Investorideas.com and energy portals and blogs (averages two thousand per month)
www.InvestorIdeas.com/About/Disclaimer.asp
Contact Investorideas.com
800 665 0411
cvanzant@investorideas.com
Visit the AAPH showcase profile at Investorideas.com
Request News and Info on AAPH
Disclosure, Disclaimer/ AAPH is a paid advertising client on Investorideas.com.
American Petro-hunter Inc. (AAPH.OB) showcase energy stock on Investorideas.com and energy portals and blogs (averages two thousand per month)
Request News and Info on AAPH
Disclosure, Disclaimer/ AAPH is a paid advertising client on Investorideas.com.
American Petro-hunter Inc. (AAPH.OB) showcase energy stock on Investorideas.com and energy portals and blogs (averages two thousand per month)
Security and Defense stock News; Visualant (OTCBB:VSUL) Issues Shareholder Letter
SEATTLE - July 18, 2011 (Investorideas.com Defense Newswire) - Visualant, Inc. (OTCBB: VSUL), a pioneer provider of industry-leading identification solutions, issued the following shareholder letter:
July 18, 2011
Dear Shareholder:
June 30, 2011 is the close of our third fiscal quarter. I want to take this opportunity to highlight the Company�s several accomplishments over the past quarter.
Visualant closed approximately $1 million in financing. This financing allows us to grow the business both internally and through acquisition.
With funding in place, we completed the acquisition of Visualant related assets from the RATLab LLC. The RATLab LLC is owned by Dr. Tom Furness, co-inventor of the Visualant Spectral Pattern Matching (�SPM�) technology. Visualant secured all rights, title and interest to the SPM technology in the important fields of use of medicine, agriculture and the environment. Additionally, Dr. Furness is now a consultant to the Company and is Visualant�s Senior Scientific Advisor. Also, as part of the RATLab asset acquisition, Dr. Brian Schowengerdt, a co-inventor of the SPM technology, joined the Company as a consultant and will be working on productizing the company�s SPM technology.
During the quarter, the Board of Directors appointed Marco Hegyi as Chairman. Mr. Hegyi, a senior technology executive formerly with Microsoft and Yahoo, is actively focused on bringing products to market which embody and exploit Visualant�s SPM technology. Working with our scientists and Visualant board member Paul R. Bonderson Jr., Mr. Hegyi is driving the rapid deployment of our technology from its current demonstration form to a market ready product that generates revenues.
Our SPM technology maps color at the photon level and with our algorithms, uses that color mapping to authenticate and diagnose. The potential for our SPM technology is so innovative and unique that it has the potential to create new industry standards and applications.
Working with Visualant consultant Lance Gima, former head of the forensic laboratory for the State of California, the Company applied for a significant grant to focus on the applications of the SPM technology in forensic science. Mr. Gima sees application for SPM technology both in crime scene and crime laboratory analytics. While there can be no assurance of success in our grant application, we intend to pursue this and other research and development grants to extend the reach and application of our SPM technology.
Visualant licensee Javelin LLC, as previously announced, is investigating environment applications of SPM technology. They are focused on detecting minute amounts of oil in water and water in aviation fuel among other target markets. Javelin performed a laboratory test where they successfully differentiated between ten vodkas. That was a stunning result which has applicability to their broad environmental diagnostic work with our SPM technology.
The acquisition of TransTech closed on June 8, 2010, and provides Visualant with approximately $10 million in annual revenues. The TransTech acquisition was financed by a three year promissory note. The note is to be paid off over 3 years, in annual installments, the first of which was paid on June 8, 2011. The remaining two payments are due in 2012 and 2013.
In early April of this year TransTech participated in the largest security industry show in the US, the International Security Show and Exposition, in Las Vegas. TransTech�s participation in the show was a great success. In addition to show-casing the various products distributed by TransTech, the Visualant SPM technology was demonstrated to a number of potential partners and end users.
In addition to participating in a number of industry trade shows and events, TransTech was busy expanding the reach and revenue of its business and is pleased to announce the following milestones this past quarter:
We encourage you to visit our website and sign up to receive information from your Company. Please do not hesitate to be in touch with us if you have any questions.
Sincerely,
Ron Erickson
Chief Executive Officer
Safe Harbor Statement
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements (within the meaning of Section 27a of the Securities Act of 1933 and Section 21e of the Securities Exchange Act of 1934) regarding us and our business, financial condition, results of operations and prospects. Forward-looking statements in this press release reflect the good faith judgment of our management and are based on facts and factors currently known to us. Forward-looking statements are subject to risks and uncertainties, and actual results and outcomes may differ materially from the results and outcomes discussed in the forward-looking statements as a result of either the matters set forth or incorporated in this press release generally or certain economic and business factors, some of which may be unknown to and/or beyond the control of Visualant, Inc. Specifically, we are exposed to various risks related to our need for additional financing to support our technology development, the sale of a significant number of our shares of common stock could depress the price of our common stock, acquiring or investing in new businesses and ongoing operations, we may incur losses in the future and the market price of our common stock may be volatile,. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. We do not undertake, and we expressly disclaim, any obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of the press release.
About Visualant, Inc.
Visualant, Inc. (OTCBB: VSUL) develops low-cost, high speed, light-based security and quality control solutions for use in homeland security, anti-counterfeiting, forgery/fraud prevention, brand protection and process control applications. Our patent-pending technology uses controlled illumination with specific bands of light, to establish a unique spectral signature for both individual and classes of items. When matched against existing databases, these spectral signatures allow precise identification and authentication of any item or substance. This breakthrough optical sensing and data capture technology is called Spectral Pattern Matching ("SPM"). SPM technology can be miniaturized and is easily integrated into a variety of hand-held or fixed mount configurations, and can be combined in the same package as a bar-code or biometric scanner.
Through its wholly owned subsidiary, TransTech Systems, Inc., the Company provides security and authentication solutions to security and law enforcement markets throughout the United States.
Contact:
Visualant, Inc.:
Lynn Felsinger
206 903 1351
Lynn@visualant.net
Investor Relations
Paul DeRiso
Core Consulting Group
925-465-6088
paul@coreconsultingroup.com
Visualant, Inc. (OTCBB:VSUL) Featured showcase company on Investorideas.com and related security portals and blogs
Visit the showcase page: http://www.investorideas.com/CO/VSUL/
Disclosure and Disclaimer: Visualant, Inc. (OTCBB:VSUL) is a paid advertising featured showcase company on Investorideas.com and related security portals and blogs.
(1500 per month and $five thousand per month in restricted 144 shares)
SEATTLE - July 18, 2011 (Investorideas.com Defense Newswire) - Visualant, Inc. (OTCBB: VSUL), a pioneer provider of industry-leading identification solutions, issued the following shareholder letter:
July 18, 2011
Dear Shareholder:
June 30, 2011 is the close of our third fiscal quarter. I want to take this opportunity to highlight the Company�s several accomplishments over the past quarter.
Visualant closed approximately $1 million in financing. This financing allows us to grow the business both internally and through acquisition.
With funding in place, we completed the acquisition of Visualant related assets from the RATLab LLC. The RATLab LLC is owned by Dr. Tom Furness, co-inventor of the Visualant Spectral Pattern Matching (�SPM�) technology. Visualant secured all rights, title and interest to the SPM technology in the important fields of use of medicine, agriculture and the environment. Additionally, Dr. Furness is now a consultant to the Company and is Visualant�s Senior Scientific Advisor. Also, as part of the RATLab asset acquisition, Dr. Brian Schowengerdt, a co-inventor of the SPM technology, joined the Company as a consultant and will be working on productizing the company�s SPM technology.
During the quarter, the Board of Directors appointed Marco Hegyi as Chairman. Mr. Hegyi, a senior technology executive formerly with Microsoft and Yahoo, is actively focused on bringing products to market which embody and exploit Visualant�s SPM technology. Working with our scientists and Visualant board member Paul R. Bonderson Jr., Mr. Hegyi is driving the rapid deployment of our technology from its current demonstration form to a market ready product that generates revenues.
Our SPM technology maps color at the photon level and with our algorithms, uses that color mapping to authenticate and diagnose. The potential for our SPM technology is so innovative and unique that it has the potential to create new industry standards and applications.
Working with Visualant consultant Lance Gima, former head of the forensic laboratory for the State of California, the Company applied for a significant grant to focus on the applications of the SPM technology in forensic science. Mr. Gima sees application for SPM technology both in crime scene and crime laboratory analytics. While there can be no assurance of success in our grant application, we intend to pursue this and other research and development grants to extend the reach and application of our SPM technology.
Visualant licensee Javelin LLC, as previously announced, is investigating environment applications of SPM technology. They are focused on detecting minute amounts of oil in water and water in aviation fuel among other target markets. Javelin performed a laboratory test where they successfully differentiated between ten vodkas. That was a stunning result which has applicability to their broad environmental diagnostic work with our SPM technology.
The acquisition of TransTech closed on June 8, 2010, and provides Visualant with approximately $10 million in annual revenues. The TransTech acquisition was financed by a three year promissory note. The note is to be paid off over 3 years, in annual installments, the first of which was paid on June 8, 2011. The remaining two payments are due in 2012 and 2013.
In early April of this year TransTech participated in the largest security industry show in the US, the International Security Show and Exposition, in Las Vegas. TransTech�s participation in the show was a great success. In addition to show-casing the various products distributed by TransTech, the Visualant SPM technology was demonstrated to a number of potential partners and end users.
In addition to participating in a number of industry trade shows and events, TransTech was busy expanding the reach and revenue of its business and is pleased to announce the following milestones this past quarter:
- A distribution agreement with Farpointe for their Access Card Programmer;
- The incorporation of access card programmer into ID card printers;
- The introduction of private labeling of ID badge bundles and supply kits for their 300 plus dealer network;
- The TransCam ID capture solution for rapid and secure ID badge creation;
- The launch of their BadgePros site at www.badgepros.com to provide technical support and information to their large dealer network; and,
- Jim Gingo, TransTech President and Visualant Board Member, continues his active involvement on the Executive Committee of the Security Industry Association. Jim currently serves as its Treasurer.
We encourage you to visit our website and sign up to receive information from your Company. Please do not hesitate to be in touch with us if you have any questions.
Sincerely,
Ron Erickson
Chief Executive Officer
Safe Harbor Statement
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements (within the meaning of Section 27a of the Securities Act of 1933 and Section 21e of the Securities Exchange Act of 1934) regarding us and our business, financial condition, results of operations and prospects. Forward-looking statements in this press release reflect the good faith judgment of our management and are based on facts and factors currently known to us. Forward-looking statements are subject to risks and uncertainties, and actual results and outcomes may differ materially from the results and outcomes discussed in the forward-looking statements as a result of either the matters set forth or incorporated in this press release generally or certain economic and business factors, some of which may be unknown to and/or beyond the control of Visualant, Inc. Specifically, we are exposed to various risks related to our need for additional financing to support our technology development, the sale of a significant number of our shares of common stock could depress the price of our common stock, acquiring or investing in new businesses and ongoing operations, we may incur losses in the future and the market price of our common stock may be volatile,. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. We do not undertake, and we expressly disclaim, any obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of the press release.
About Visualant, Inc.
Visualant, Inc. (OTCBB: VSUL) develops low-cost, high speed, light-based security and quality control solutions for use in homeland security, anti-counterfeiting, forgery/fraud prevention, brand protection and process control applications. Our patent-pending technology uses controlled illumination with specific bands of light, to establish a unique spectral signature for both individual and classes of items. When matched against existing databases, these spectral signatures allow precise identification and authentication of any item or substance. This breakthrough optical sensing and data capture technology is called Spectral Pattern Matching ("SPM"). SPM technology can be miniaturized and is easily integrated into a variety of hand-held or fixed mount configurations, and can be combined in the same package as a bar-code or biometric scanner.
Through its wholly owned subsidiary, TransTech Systems, Inc., the Company provides security and authentication solutions to security and law enforcement markets throughout the United States.
Contact:
Visualant, Inc.:
Lynn Felsinger
206 903 1351
Lynn@visualant.net
Investor Relations
Paul DeRiso
Core Consulting Group
925-465-6088
paul@coreconsultingroup.com
Visualant, Inc. (OTCBB:VSUL) Featured showcase company on Investorideas.com and related security portals and blogs
Visit the showcase page: http://www.investorideas.com/CO/VSUL/
Disclosure and Disclaimer: Visualant, Inc. (OTCBB:VSUL) is a paid advertising featured showcase company on Investorideas.com and related security portals and blogs.
(1500 per month and $five thousand per month in restricted 144 shares)
Pharma Stock News; BioSante Pharmaceuticals (NASDAQ: BPAX) Announces Management Team Additions
LINCOLNSHIRE, Ill. - July 18, 2011 (Investorideas.com newswire) - BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX), today announced the appointment of Sandra Croak-Brossman, MS, Ph.D., as Vice President, Regulatory Affairs and Quality Assurance, and Patricia M. Adams, MS as Vice President, Human Resources. Dr. Croak-Brossman assumed this new role effective today. Ms. Adams assumed her new role effective in May 2011.
Dr. Croak-Brossman joins BioSante with over 24 years of experience in the pharmaceutical industry. She has held a variety of regulatory positions and has led operations at both a U.S. and global level. Dr. Croak-Brossman�s work experience includes positions at Boehringer Ingelheim, Pfizer and Abbott Laboratories. Importantly, while at Pfizer, Dr. Croak-Brossman was the worldwide regulatory lead for Viagra�. Her experience as a regulatory lead in the sexual dysfunction therapeutic market makes her uniquely qualified to manage regulatory projects as BioSante progresses towards the NDA submission for LibiGel� (testosterone gel). Dr. Croak-Brossman earned her MS and Ph.D. in Quantitative Genetics and Animal Breeding from Purdue University and conducted her Post-Doctoral Fellowship at Cornell University.
Ms. Adams has over 20 years of experience in the pharmaceutical industry. From 2009 through May 2011, Ms. Adams was with Lundbeck Inc. (the U.S. subsidiary of H. Lundbeck A/S based in Copenhagen, Denmark) where she most recently served as the Vice President of Human Resources. Prior to joining Lundbeck, Ms. Adams was employed by Takeda Pharmaceuticals North America from 1998 � 2009. While at Takeda, Ms. Adams held positions of increasing responsibility in both Human Resources and Sales Operations and created foundational policies and procedures to support the launch of Takeda�s North American headquarters. Ms. Adams� previous work experiences also include time at both TAP Pharmaceuticals and Abbott Laboratories. Ms. Adams earned her MS in Human Resources from Loyola University Chicago and her Senior Professional in Human Resources certification from The Human Resources Certification Institute.
"We are very pleased to have both Sandra Croak-Brossman and Patricia Adams joining us at this exciting time for BioSante," said Stephen M. Simes, BioSante�s president and chief executive officer. "Sandy�s experience and expertise, particularly in leading Pfizer�s Viagra to an FDA approval, will be invaluable in view of the excellent progress we have made in the development of LibiGel for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is no FDA-approved product. Patty has a clear vision for where HR needs to go and how to help BioSante recruit, retain and develop the best talent in the pharmaceutical industry. We remain dedicated to our objective of maximizing stockholder value and believe Sandy and Patty will be integral to this endeavor."
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is seeking opportunities for its other technologies. Additional information is available online at: www.biosantepharma.com.
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products, the timing of anticipated regulatory submissions and other statements identified by words such as "will," "continue," "could," "believe," "intends," "continue," "expects," "anticipates," "estimates," "may," other words of similar meaning, derivations of such words or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly report on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact:
BioSante Pharmaceuticals
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Media:
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316
azachary@mckinneychicago.com
BioSante Pharmaceuticals, Inc: (NASDAQ: BPAX) is a featured showcase biotech/pharma stock on Investorideas.com
Request news, updates and trading alerts on BPAX and other showcase stocks http://www.investorideas.com/Resources/Newsletter.asp
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including biotech and pharma stocks.
Disclaimer: The following news/content is paid for as part of the BPAX showcase program (two thousand per month) Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Source: Investorideas.com, BioSante, Investorideas.com
800 665 0411 cvanzant@investorideas.com
LINCOLNSHIRE, Ill. - July 18, 2011 (Investorideas.com newswire) - BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX), today announced the appointment of Sandra Croak-Brossman, MS, Ph.D., as Vice President, Regulatory Affairs and Quality Assurance, and Patricia M. Adams, MS as Vice President, Human Resources. Dr. Croak-Brossman assumed this new role effective today. Ms. Adams assumed her new role effective in May 2011.
Dr. Croak-Brossman joins BioSante with over 24 years of experience in the pharmaceutical industry. She has held a variety of regulatory positions and has led operations at both a U.S. and global level. Dr. Croak-Brossman�s work experience includes positions at Boehringer Ingelheim, Pfizer and Abbott Laboratories. Importantly, while at Pfizer, Dr. Croak-Brossman was the worldwide regulatory lead for Viagra�. Her experience as a regulatory lead in the sexual dysfunction therapeutic market makes her uniquely qualified to manage regulatory projects as BioSante progresses towards the NDA submission for LibiGel� (testosterone gel). Dr. Croak-Brossman earned her MS and Ph.D. in Quantitative Genetics and Animal Breeding from Purdue University and conducted her Post-Doctoral Fellowship at Cornell University.
Ms. Adams has over 20 years of experience in the pharmaceutical industry. From 2009 through May 2011, Ms. Adams was with Lundbeck Inc. (the U.S. subsidiary of H. Lundbeck A/S based in Copenhagen, Denmark) where she most recently served as the Vice President of Human Resources. Prior to joining Lundbeck, Ms. Adams was employed by Takeda Pharmaceuticals North America from 1998 � 2009. While at Takeda, Ms. Adams held positions of increasing responsibility in both Human Resources and Sales Operations and created foundational policies and procedures to support the launch of Takeda�s North American headquarters. Ms. Adams� previous work experiences also include time at both TAP Pharmaceuticals and Abbott Laboratories. Ms. Adams earned her MS in Human Resources from Loyola University Chicago and her Senior Professional in Human Resources certification from The Human Resources Certification Institute.
"We are very pleased to have both Sandra Croak-Brossman and Patricia Adams joining us at this exciting time for BioSante," said Stephen M. Simes, BioSante�s president and chief executive officer. "Sandy�s experience and expertise, particularly in leading Pfizer�s Viagra to an FDA approval, will be invaluable in view of the excellent progress we have made in the development of LibiGel for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is no FDA-approved product. Patty has a clear vision for where HR needs to go and how to help BioSante recruit, retain and develop the best talent in the pharmaceutical industry. We remain dedicated to our objective of maximizing stockholder value and believe Sandy and Patty will be integral to this endeavor."
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is seeking opportunities for its other technologies. Additional information is available online at: www.biosantepharma.com.
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products, the timing of anticipated regulatory submissions and other statements identified by words such as "will," "continue," "could," "believe," "intends," "continue," "expects," "anticipates," "estimates," "may," other words of similar meaning, derivations of such words or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly report on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact:
BioSante Pharmaceuticals
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Media:
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316
azachary@mckinneychicago.com
BioSante Pharmaceuticals, Inc: (NASDAQ: BPAX) is a featured showcase biotech/pharma stock on Investorideas.com
Request news, updates and trading alerts on BPAX and other showcase stocks http://www.investorideas.com/Resources/Newsletter.asp
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including biotech and pharma stocks.
Disclaimer: The following news/content is paid for as part of the BPAX showcase program (two thousand per month) Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Source: Investorideas.com, BioSante, Investorideas.com
800 665 0411 cvanzant@investorideas.com
Consumer/ Retail Stocks; Major Oil Company to Support Comprehensive Test of YesDTC's (OTCBB:YESD) MotorBooster Engine Catalyst Product - Product Already Showing 16.5% Fuel Savings
SAN FRANCISCO - July 18, 2011 (Investorideas.com newswire) - YesDTC Holdings, Inc. (OTCBB:YESD), a direct-to-consumer marketer and global distributor of consumer goods and products, today announced another significant development involving the recently announced performance test of its MotorBooster(TM) fuel catalyst formulation being conducted by the University of Alaska, Fairbanks (UAF). In addition to tests by the UAF, a major Alaskan oil exploration company has also expressed significant interest in the testing protocol and has stated its intent, assuming favorable test results of MotorBooster by the UAF, to employ one or more of the products across its entire fleet.
Recent fuel catalyst technologies have changed significantly from earlier versions and are now yielding strong results. YesDTC has already completed one highly successful test of this technology in conjunction with a leading NASCAR and Winston Cup development team that demonstrated a 16.5% reduction in fuel consumption and an even more significant reduction in hydrocarbon emissions. This additional test of MotorBooster by the University of Alaska is designed to further demonstrate the unique fuel savings and emission reduction capabilities of this proprietary engine catalyst.
Christian Kirsebom, General Manager of YesDTC commented, "This is a highly significant event for our Company. The science behind fuel catalysts has advanced meaningfully over the past few years and is beginning to attract a lot of attention within the scientific community. Our first test was very successful and we are confident this new test with the University of Alaska, Fairbanks will yield similar results. Being mindful of the revolutionary impact the MotorBooster product is showing to have on increasing fuel efficiency and decreasing emissions, something that could be a game changer for any industry using oil and gas fuels, we think its important to position the marketing of this product with overwhelming scientific evidence in support of its efficacy as we ready for a nationwide rollout over the coming months."
Mr. Kirsebom continued, "At a national average of $3.76 per gallon for regular, and $3.92 for premium, a 16% increase in fuel efficiency as demonstrated by the Company's last independent test would mean a $0.60 savings per gallon on regular and a very significant $0.63 savings on premium, while users switching from premium to regular as a result of using MotorBooster would realize even more significant savings. We believe consumers will be very interested in achieving similar results as we roll this product out into the marketplace."
As an automotive combustion catalyst that targets the consumer market, MotorBooster is designed to increase fuel economy, reduce hydrocarbon emissions and enhance engine performance. MotorBooster(TM) is a proprietary formulation tablet that users simply insert into their gas tank, upon which it dissolves into the fuel to achieve mileage, emissions and enhancement benefits, including allowing motorists to use lower octane fuels for double-savings at the pump. MotorBooster is protected under U.S. patents and has received EPA Certification to not cause engine damage.
About YesDTC Holdings, Inc.
YesDTC Holdings, Inc. is a direct-to-consumer marketing company specializing in direct response television (DRTV), Internet and retail marketing programs. The Company brings a unique set of skills to this market space. YesDTC combines both the creative talents and financial acumen needed to create a total package for direct-to-consumer marketing programs. Importantly, the Company also maintains a strategic partnership with Schulberg Media Works (SMW), a pioneering media production firm in the direct-to-consumer space with a highly acclaimed list of successful client campaigns and product infomercials. The Company's infomercial for its MediPendant product can be seen at www.medipendant.com. Information on NutriFusion can be seen at www.nutrifusion.com and information about the Company's newest offering from Alo Networks can be found at http://www.alonetworks.com/. More information on YesDTC Holdings can be found at www.yesdtc.com.
Forward-Looking Statements
Certain statements in this press release may constitute "forward-looking statements" that involve risks and uncertainties. These include statements about our expectations, plans, objectives, assumptions or future events. You should not place undue reliance on these forward-looking statements. Information concerning factors that could cause our actual results to differ materially from these forward-looking statements can be found in our periodic reports filed with the Securities and Exchange Commission. We undertake no obligation to publicly release revisions to these forward-looking statements to reflect future events or circumstances or reflect the occurrence of unanticipated events.
Contact:
YesDTC Holdings, Inc.
Christian Kirsebom
(925) 247-6666
Contact Investorideas.com
dvanzant@investorideas.com
Visit the YESD showcase profile at Investorideas.com
http://www.investorideas.com/CO/YESD/
Request News and Info on YESD
Disclosure, Disclaimer/ YESD is a paid advertising client on Investorideas.com.
YESD: one time fee of five thousand cash and three hundred thousand 144 shares
About Investorideas.com
- Investor Ideas the can change the world
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics
Investor Protection and Regulation for Pinks sheets: http://www.pinksheets.com/otcguide/investors_protection.jsp
SAN FRANCISCO - July 18, 2011 (Investorideas.com newswire) - YesDTC Holdings, Inc. (OTCBB:YESD), a direct-to-consumer marketer and global distributor of consumer goods and products, today announced another significant development involving the recently announced performance test of its MotorBooster(TM) fuel catalyst formulation being conducted by the University of Alaska, Fairbanks (UAF). In addition to tests by the UAF, a major Alaskan oil exploration company has also expressed significant interest in the testing protocol and has stated its intent, assuming favorable test results of MotorBooster by the UAF, to employ one or more of the products across its entire fleet.
Recent fuel catalyst technologies have changed significantly from earlier versions and are now yielding strong results. YesDTC has already completed one highly successful test of this technology in conjunction with a leading NASCAR and Winston Cup development team that demonstrated a 16.5% reduction in fuel consumption and an even more significant reduction in hydrocarbon emissions. This additional test of MotorBooster by the University of Alaska is designed to further demonstrate the unique fuel savings and emission reduction capabilities of this proprietary engine catalyst.
Christian Kirsebom, General Manager of YesDTC commented, "This is a highly significant event for our Company. The science behind fuel catalysts has advanced meaningfully over the past few years and is beginning to attract a lot of attention within the scientific community. Our first test was very successful and we are confident this new test with the University of Alaska, Fairbanks will yield similar results. Being mindful of the revolutionary impact the MotorBooster product is showing to have on increasing fuel efficiency and decreasing emissions, something that could be a game changer for any industry using oil and gas fuels, we think its important to position the marketing of this product with overwhelming scientific evidence in support of its efficacy as we ready for a nationwide rollout over the coming months."
Mr. Kirsebom continued, "At a national average of $3.76 per gallon for regular, and $3.92 for premium, a 16% increase in fuel efficiency as demonstrated by the Company's last independent test would mean a $0.60 savings per gallon on regular and a very significant $0.63 savings on premium, while users switching from premium to regular as a result of using MotorBooster would realize even more significant savings. We believe consumers will be very interested in achieving similar results as we roll this product out into the marketplace."
As an automotive combustion catalyst that targets the consumer market, MotorBooster is designed to increase fuel economy, reduce hydrocarbon emissions and enhance engine performance. MotorBooster(TM) is a proprietary formulation tablet that users simply insert into their gas tank, upon which it dissolves into the fuel to achieve mileage, emissions and enhancement benefits, including allowing motorists to use lower octane fuels for double-savings at the pump. MotorBooster is protected under U.S. patents and has received EPA Certification to not cause engine damage.
About YesDTC Holdings, Inc.
YesDTC Holdings, Inc. is a direct-to-consumer marketing company specializing in direct response television (DRTV), Internet and retail marketing programs. The Company brings a unique set of skills to this market space. YesDTC combines both the creative talents and financial acumen needed to create a total package for direct-to-consumer marketing programs. Importantly, the Company also maintains a strategic partnership with Schulberg Media Works (SMW), a pioneering media production firm in the direct-to-consumer space with a highly acclaimed list of successful client campaigns and product infomercials. The Company's infomercial for its MediPendant product can be seen at www.medipendant.com. Information on NutriFusion can be seen at www.nutrifusion.com and information about the Company's newest offering from Alo Networks can be found at http://www.alonetworks.com/. More information on YesDTC Holdings can be found at www.yesdtc.com.
Forward-Looking Statements
Certain statements in this press release may constitute "forward-looking statements" that involve risks and uncertainties. These include statements about our expectations, plans, objectives, assumptions or future events. You should not place undue reliance on these forward-looking statements. Information concerning factors that could cause our actual results to differ materially from these forward-looking statements can be found in our periodic reports filed with the Securities and Exchange Commission. We undertake no obligation to publicly release revisions to these forward-looking statements to reflect future events or circumstances or reflect the occurrence of unanticipated events.
Contact:
YesDTC Holdings, Inc.
Christian Kirsebom
(925) 247-6666
Contact Investorideas.com
dvanzant@investorideas.com
Visit the YESD showcase profile at Investorideas.com
http://www.investorideas.com/CO/YESD/
Request News and Info on YESD
Disclosure, Disclaimer/ YESD is a paid advertising client on Investorideas.com.
YESD: one time fee of five thousand cash and three hundred thousand 144 shares
About Investorideas.com
- Investor Ideas the can change the world
Sign up for free stock alerts and news:
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.http://www.investorideas.com/Resources/Newsletter.asp
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics
Investor Protection and Regulation for Pinks sheets: http://www.pinksheets.com/otcguide/investors_protection.jsp
Oil and Gas Stocks News; American Petro-Hunter (OTCBB: AAPH) Announces Drilling Plans for 11 Horizontal Wells at North Oklahoma Project
SCOTTSDALE, AZ - July 18, 2011 (Investorideas.com energy newswire) - American Petro-Hunter, Inc. (OTC.BB:AAPH) ("American Petro-Hunter" or the "Company") is pleased to announce updated plans regarding the Company's continued participation in a proposed field development horizontal drilling program of the Mississippi formation at the North Oklahoma Project.
Based on the commercial success of the recent NOM-1H horizontal well, the Company and working interest partners have determined that the development plan for this newly defined Mississippi oil and gas reservoir can accommodate the drilling of a minimum of 11 horizontal wells.
The drilling schedule, which includes direct offsets to the producing NOM-1H, will involve the drilling of approximately one horizontal Mississippi well every 30 to 60 days with plans to commence the program in early September. The schedule allows for a predictable time frame to drill, complete and put in requisite production facilities for both oil sales plus a gas line hook up every other month.
This aggressive drilling schedule signifies there will be well drilling, completion and potential production activity on the Ripley project leases for the remainder of 2011 and throughout 2012. In total, 12 production wells are targeted for the full development of the project.
The operator has further advised the Company that the same group of professional oil and gas contractors and engineers will be involved in all aspects of the engineering design, vertical and directional drilling of the proposed program as the group performed well above expectations on the drilling and completion of the NOM-1H well.
Company President Robert McIntosh states, "We couldn't be more pleased with the proposed engineering plans to drill 11 more horizontal wells on the Ripley leases. Our commitment to this project is indicative of how this area has become a core asset and means we aim to be very busy drilling wells in this area for the foreseeable future. The continued success of this project is poised to dictate our growth and will prove instrumental in meeting our long range production targets."
About American Petro-Hunter, Inc. (OTCBB: AAPH)
The Company is a goal-oriented exploration and production (E&P) Company aiming to become an intermediate level oil and gas producer within 12 months. The Company is in production at the Poston Project in Trego County Kansas with new drilling activity and production underway at the North Oklahoma Oil Project. With the achievable target of becoming a 1000 BOE producer as our goal, American Petro-Hunter is actively on the "hunt" for domestic petroleum assets. Visit us at: www.americanpetrohunter.com
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of our exploration program at our properties and any anticipated future production. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with petroleum exploration and development stage exploration companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-KSB for the most recent fiscal year, our quarterly reports on Form 10-QSB and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
American Petro-Hunter, Inc.
Robert McIntosh
President & C.E.O.
To find out more about American Petro-Hunter, Inc. (OTC.BB:AAPH), visit our website at www.americanpetrohunter.com
Contact:
Investor Relations:
Mountainview IR Services, Inc.
1-888-521-7762
investors@americanpetrohunterinc.com
SCOTTSDALE, AZ - July 18, 2011 (Investorideas.com energy newswire) - American Petro-Hunter, Inc. (OTC.BB:AAPH) ("American Petro-Hunter" or the "Company") is pleased to announce updated plans regarding the Company's continued participation in a proposed field development horizontal drilling program of the Mississippi formation at the North Oklahoma Project.
Based on the commercial success of the recent NOM-1H horizontal well, the Company and working interest partners have determined that the development plan for this newly defined Mississippi oil and gas reservoir can accommodate the drilling of a minimum of 11 horizontal wells.
The drilling schedule, which includes direct offsets to the producing NOM-1H, will involve the drilling of approximately one horizontal Mississippi well every 30 to 60 days with plans to commence the program in early September. The schedule allows for a predictable time frame to drill, complete and put in requisite production facilities for both oil sales plus a gas line hook up every other month.
This aggressive drilling schedule signifies there will be well drilling, completion and potential production activity on the Ripley project leases for the remainder of 2011 and throughout 2012. In total, 12 production wells are targeted for the full development of the project.
The operator has further advised the Company that the same group of professional oil and gas contractors and engineers will be involved in all aspects of the engineering design, vertical and directional drilling of the proposed program as the group performed well above expectations on the drilling and completion of the NOM-1H well.
Company President Robert McIntosh states, "We couldn't be more pleased with the proposed engineering plans to drill 11 more horizontal wells on the Ripley leases. Our commitment to this project is indicative of how this area has become a core asset and means we aim to be very busy drilling wells in this area for the foreseeable future. The continued success of this project is poised to dictate our growth and will prove instrumental in meeting our long range production targets."
About American Petro-Hunter, Inc. (OTCBB: AAPH)
The Company is a goal-oriented exploration and production (E&P) Company aiming to become an intermediate level oil and gas producer within 12 months. The Company is in production at the Poston Project in Trego County Kansas with new drilling activity and production underway at the North Oklahoma Oil Project. With the achievable target of becoming a 1000 BOE producer as our goal, American Petro-Hunter is actively on the "hunt" for domestic petroleum assets. Visit us at: www.americanpetrohunter.com
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of our exploration program at our properties and any anticipated future production. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with petroleum exploration and development stage exploration companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-KSB for the most recent fiscal year, our quarterly reports on Form 10-QSB and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
American Petro-Hunter, Inc.
Robert McIntosh
President & C.E.O.
To find out more about American Petro-Hunter, Inc. (OTC.BB:AAPH), visit our website at www.americanpetrohunter.com
Contact:
Investor Relations:
Mountainview IR Services, Inc.
1-888-521-7762
investors@americanpetrohunterinc.com
Visit the AAPH showcase profile at Investorideas.com
Request News and Info on AAPH
Disclosure, Disclaimer/ AAPH is a paid advertising client on Investorideas.com.
American Petro-hunter Inc. (AAPH.OB) showcase energy stock on Investorideas.com and energy portals and blogs (averages two thousand per month)
Request News and Info on AAPH
Disclosure, Disclaimer/ AAPH is a paid advertising client on Investorideas.com.
American Petro-hunter Inc. (AAPH.OB) showcase energy stock on Investorideas.com and energy portals and blogs (averages two thousand per month)
Friday, July 15, 2011
Biotech/Medical Technology Stock News; Aethlon Medical (OTCBB: AEMD) Releases Shareholder Letter
SAN DIEGO – July 15, 2011 (Investorideas.com newswire) - Aethlon Medical, Inc. (OTCBB: AEMD) disclosed today that its Chairman and CEO, James A. Joyce, has issued the following letter to shareholders.
To our Shareholders:
Last December, I authored a shareholder letter which referenced the viewpoint of healthcare leaders who felt a need for innovative new therapeutic strategies to evolve as escalating regulatory costs, challenges and uncertainties made it nearly impossible for small to mid-size organizations to commercialize their drug candidates. In response, we introduced the Aethlon ADAPT™ (Adaptive Dialysis-Like Affinity Platform Technology) system, as an innovative medical device platform that provides a basis to create new therapeutic devices through the convergence of affinity drug agents and plasma membrane technologies. The Aethlon ADAPT™ system provides a previously unrecognized commercialization pathway to antibody and other affinity drug developers, who should also appreciate a less onerous medical device regulatory pathway. We are already seeing evidence of our ADAPT™ system being the impetus for industry collaborations that offer new channels of early revenue generation.
On May 25th, we introduced our Aethlon ADAPT™ system to the drug industry at the C21 Life Sciences Partnering Conference. However, we had already begun to leverage our ADAPT™ system on April 1st, through a response to a government contract opportunity offered by the Defense Advanced Research Projects Agency (DARPA) entitled, "Dialysis-Like Therapeutics." Included within our response was a proposal to develop a device that would reduce the incidence of sepsis in wounded war-fighters. I am pleased to inform you that our submitted program was chosen for funding by a panel of experts assembled by DARPA. While it is an honor to be chosen to receive a contract award, I ask that you curb any assumption that we have won a contract based on information that may be published on the Internet. A contract that leads to funding of our proposed program is predicated on the successful completion of a detailed contracting process. On June 29th, we again leveraged the capabilities of our ADAPT™ system through a response to a U.S. Army initiative to create a device that would meet the objective of a program entitled "Blood Purification for Organ Failure."
The genesis of the Aethlon ADAPT™ system is our Hemopurifier®, a device that has demonstrated broad-spectrum activity against infectious viral pathogens, immunosuppressive proteins and exosomes secreted by cancer. Increasingly, exosomes are being discovered to have implications in other life-threatening diseases. Next Tuesday (July 19th), we will meet with FDA officials to discuss a proposed clinical program to support the regulatory advancement of our Hemopurifier® as a treatment countermeasure against bioterror and pandemic threats. Based on data collected from clinical programs conducted in India, we will also seek permission from the FDA to expand our treatment indications to include Hepatitis C virus (HCV). Formal FDA feedback to next week's meeting would likely occur in early fall. Should the FDA grant permission to initiate our U.S. clinical studies, we have already submitted (on May 31st of this year) a request to the Biomedical Advanced Research and Development Authority (BARDA) to fund clinical programs specific to bioterror and pandemic threats. In the meantime, we continue to advance our HCV treatment program at the Medanta Medicity Institute. As previously communicated, positive clinical outcomes from this study will lead to commercialization of our Hemopurifier® in India. Regardless of the many challenges we have confronted, we continue to advance our mission to create innovative devices that address unmet medical needs in cancer, infectious disease and other life-threatening conditions. On behalf of your dedicated team at Aethlon Medical, I again thank you for your continued support and belief in our endeavors.
Very truly yours,
James A. Joyce
Chairman, CEO
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the ability for the Company to derive business partnerships or future revenue streams using the Aethlon ADAPT™ system including consummating government contracts or grants, the FDA's willingness to allow the Company to proceed with the clinical trials proposed in the re-initiation of an Investigational Device Exemption (IDE) study, or the FDA's willingness to meet with company officials to discuss Emergency Use Authorization (EUA) for the Hemopurifier® as a broad-spectrum countermeasure against untreatable viral threats, the Company's ability to conduct clinical trials in Europe or to achieve regulatory approval in Europe, the Company's ability to commercialize its Hemopurifier® in India, the capability of the Hemopurifier® to reduce viral loads and other disease conditions or to identify or treat disease conditions such as cancer or Hepatitis-C, including the ability to capture exosomes and the impact that potential ability may have on disease conditions, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com
Jody Cain
Senior Vice President, Lippert/Heilshorn & Associates
310.691.7100
jcain@lhai.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
John P. Salvador
Director, Communications & Investor Relations
858.459.7800 x307
jps@aethlonmedical.com
SAN DIEGO – July 15, 2011 (Investorideas.com newswire) - Aethlon Medical, Inc. (OTCBB: AEMD) disclosed today that its Chairman and CEO, James A. Joyce, has issued the following letter to shareholders.
To our Shareholders:
Last December, I authored a shareholder letter which referenced the viewpoint of healthcare leaders who felt a need for innovative new therapeutic strategies to evolve as escalating regulatory costs, challenges and uncertainties made it nearly impossible for small to mid-size organizations to commercialize their drug candidates. In response, we introduced the Aethlon ADAPT™ (Adaptive Dialysis-Like Affinity Platform Technology) system, as an innovative medical device platform that provides a basis to create new therapeutic devices through the convergence of affinity drug agents and plasma membrane technologies. The Aethlon ADAPT™ system provides a previously unrecognized commercialization pathway to antibody and other affinity drug developers, who should also appreciate a less onerous medical device regulatory pathway. We are already seeing evidence of our ADAPT™ system being the impetus for industry collaborations that offer new channels of early revenue generation.
On May 25th, we introduced our Aethlon ADAPT™ system to the drug industry at the C21 Life Sciences Partnering Conference. However, we had already begun to leverage our ADAPT™ system on April 1st, through a response to a government contract opportunity offered by the Defense Advanced Research Projects Agency (DARPA) entitled, "Dialysis-Like Therapeutics." Included within our response was a proposal to develop a device that would reduce the incidence of sepsis in wounded war-fighters. I am pleased to inform you that our submitted program was chosen for funding by a panel of experts assembled by DARPA. While it is an honor to be chosen to receive a contract award, I ask that you curb any assumption that we have won a contract based on information that may be published on the Internet. A contract that leads to funding of our proposed program is predicated on the successful completion of a detailed contracting process. On June 29th, we again leveraged the capabilities of our ADAPT™ system through a response to a U.S. Army initiative to create a device that would meet the objective of a program entitled "Blood Purification for Organ Failure."
The genesis of the Aethlon ADAPT™ system is our Hemopurifier®, a device that has demonstrated broad-spectrum activity against infectious viral pathogens, immunosuppressive proteins and exosomes secreted by cancer. Increasingly, exosomes are being discovered to have implications in other life-threatening diseases. Next Tuesday (July 19th), we will meet with FDA officials to discuss a proposed clinical program to support the regulatory advancement of our Hemopurifier® as a treatment countermeasure against bioterror and pandemic threats. Based on data collected from clinical programs conducted in India, we will also seek permission from the FDA to expand our treatment indications to include Hepatitis C virus (HCV). Formal FDA feedback to next week's meeting would likely occur in early fall. Should the FDA grant permission to initiate our U.S. clinical studies, we have already submitted (on May 31st of this year) a request to the Biomedical Advanced Research and Development Authority (BARDA) to fund clinical programs specific to bioterror and pandemic threats. In the meantime, we continue to advance our HCV treatment program at the Medanta Medicity Institute. As previously communicated, positive clinical outcomes from this study will lead to commercialization of our Hemopurifier® in India. Regardless of the many challenges we have confronted, we continue to advance our mission to create innovative devices that address unmet medical needs in cancer, infectious disease and other life-threatening conditions. On behalf of your dedicated team at Aethlon Medical, I again thank you for your continued support and belief in our endeavors.
Very truly yours,
James A. Joyce
Chairman, CEO
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the ability for the Company to derive business partnerships or future revenue streams using the Aethlon ADAPT™ system including consummating government contracts or grants, the FDA's willingness to allow the Company to proceed with the clinical trials proposed in the re-initiation of an Investigational Device Exemption (IDE) study, or the FDA's willingness to meet with company officials to discuss Emergency Use Authorization (EUA) for the Hemopurifier® as a broad-spectrum countermeasure against untreatable viral threats, the Company's ability to conduct clinical trials in Europe or to achieve regulatory approval in Europe, the Company's ability to commercialize its Hemopurifier® in India, the capability of the Hemopurifier® to reduce viral loads and other disease conditions or to identify or treat disease conditions such as cancer or Hepatitis-C, including the ability to capture exosomes and the impact that potential ability may have on disease conditions, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com
Jody Cain
Senior Vice President, Lippert/Heilshorn & Associates
310.691.7100
jcain@lhai.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
John P. Salvador
Director, Communications & Investor Relations
858.459.7800 x307
jps@aethlonmedical.com
AETHLON MEDICAL INC (OTC BB: AEMD) is a Showcase biotech, biodefense and defense stock on Investorideas.com
Visit the AETHLON MEDICAL INC (OTC BB: AEMD) showcase profile page
Disclosure/Disclaimer: AETHLON MEDICAL INC (OTC BB: AEMD) is a paid advertising client ($one thousand five hundred per month, $five thousand per month in 144 stock)
Visit the AETHLON MEDICAL INC (OTC BB: AEMD) showcase profile page
Defense and Security Stocks; United Protection Security Group Inc. (TSX-V: UZZ) - Acquisition Closing Date re-scheduled
Edmonton, Alberta CANADA - July 15, 2011 (InvestorIdeas.com Newswire) - United Protection Security Group Inc. (TSX-V:UZZ) (UPSG or the Company), announces that the Closing Date for the acquisition of an Edmonton based Video Verification Security Systems company ("the Target"), as previously reported on June 14, 2011, has been postponed until August 31, 2011. The acquisition of the Target will be subject to the preparation and execution of a Definitive Purchase Agreement, as well as obtaining the approval of the board of directors and the TSX Venture Exchange, prior to that date.
Stock Awareness Activities
To find out more about United Protection Security Group Inc. (TSX-V: UZZ), visit our website at www.unitedprotection.com. To join the 'request for information', go to the web page www.unitedprotection.com and click the tab 'request information' and follow the prompts.
For additional investor and media relations inquiries contact:
Fredy Ramsoondar CEO and Director
Email: fredy.ramsoondar@unitedprotection.com
Tel: 780-465-8101
Statements in this press release other than purely historical information, including statements relating to the Company's future plans and objectives or expected results, are forward-looking statements. Forward-looking statements are based on numerous assumptions and are subject to all of the risks and uncertainties inherent in the Company's business, including risks related to business development and retention, and risks related to the current economic and credit conditions. As a result, actual results may vary materially from those described in the forward-looking statements.
The TSX Venture Exchange has neither approved nor disapproved the information contained herein.
United Protection Security Group Inc. (TSX - V: UZZ)
#212, 8711A - 50th Street, Edmonton, Alberta T6B 1E7
Telephone (780) 465-8101
To view this press release as a web page, click onto the link below:
www.usetdas.com/PR/unitedprotection15072011.htm
Source: United Protection Security Group Inc. (TSX-V: UZZ) http://www.unitedprotection.com
Maximum News Dissemination by Filing Services Canada Inc. http://www.usetdas.com
Disclosure: UZZ is a paid advertising client on Investorideas.com and our defense portals.
Edmonton, Alberta CANADA - July 15, 2011 (InvestorIdeas.com Newswire) - United Protection Security Group Inc. (TSX-V:UZZ) (UPSG or the Company), announces that the Closing Date for the acquisition of an Edmonton based Video Verification Security Systems company ("the Target"), as previously reported on June 14, 2011, has been postponed until August 31, 2011. The acquisition of the Target will be subject to the preparation and execution of a Definitive Purchase Agreement, as well as obtaining the approval of the board of directors and the TSX Venture Exchange, prior to that date.
Stock Awareness Activities
To find out more about United Protection Security Group Inc. (TSX-V: UZZ), visit our website at www.unitedprotection.com. To join the 'request for information', go to the web page www.unitedprotection.com and click the tab 'request information' and follow the prompts.
For additional investor and media relations inquiries contact:
Fredy Ramsoondar CEO and Director
Email: fredy.ramsoondar@unitedprotection.com
Tel: 780-465-8101
Statements in this press release other than purely historical information, including statements relating to the Company's future plans and objectives or expected results, are forward-looking statements. Forward-looking statements are based on numerous assumptions and are subject to all of the risks and uncertainties inherent in the Company's business, including risks related to business development and retention, and risks related to the current economic and credit conditions. As a result, actual results may vary materially from those described in the forward-looking statements.
The TSX Venture Exchange has neither approved nor disapproved the information contained herein.
United Protection Security Group Inc. (TSX - V: UZZ)
#212, 8711A - 50th Street, Edmonton, Alberta T6B 1E7
Telephone (780) 465-8101
To view this press release as a web page, click onto the link below:
www.usetdas.com/PR/unitedprotection15072011.htm
Source: United Protection Security Group Inc. (TSX-V: UZZ) http://www.unitedprotection.com
Maximum News Dissemination by Filing Services Canada Inc. http://www.usetdas.com
Disclosure: UZZ is a paid advertising client on Investorideas.com and our defense portals.
Interview with Mr. Stephen M. Simes, President and CEO of BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), Discusses the Potential of Future Partners or Acquisition
Point Roberts, WA, LINCOLNSHIRE, Ill – July 15, 2011 –(Investorideas.com newswire.com) Investorideas.com, an investor research portal covering leading sectors including biotech and pharma stocks, features an exclusive Q&A interview with Mr. Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals, as industry buzz builds on talk of partners or acquisition with value up to $1 Billion.
As BioSante's lead product LibiGel ® (transdermal testosterone gel), for the treatment of female sexual dysfunction gets closer to market, the company is now on the radar as a biotech company to watch.
BioSante Pharmaceuticals Interview
Q: Investorideas.com
Stephen, there is an old saying in the market, that the trading tells the story. The activity and interest in your stock is building from both analysts and retail investors. Can you give us some insight to the key points of the recent analyst coverage and what the industry is saying about your company?
A: Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals
We have been in development of LibiGel for quite a number of years. Finally the finish line is in site. We have completed enrollment of women into our three LibiGel Phase III clinical studies and efficacy data should be available in the fourth quarter of this year. Safety data should be available in the third quarter of 2012 and our objective is to submit the LibiGel new drug application (NDA) to the FDA in the fourth quarter of 2012. All of these dates are near-term opportunities in the biotech/pharma world. Analysts and investors are taking note of the progress we have made with LibiGel.
Q: Investorideas.com
Can you discuss the potential dollar value for a female sexual dysfunction drug hitting the market?
A: Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals
We believe the market for a drug for female sexual dysfunction is potentially bigger than the market for erectile dysfunction drugs, a $2 billion market if the U.S., and male testosterone, a $1.3 billion market in the U.S. Our belief is based on current off-label use of products to treat female sexual dysfunction as well as publications that indicate the potential size of the market for treatment of female sexual dysfunction. It has been over 13 years since Viagra was approved and we believe strongly that women deserve an FDA-approved therapeutic choice for their sexual health issues.
Q: Investorideas.com
With LibiGel ® getting closer to market, how will the process of potential partners or acquisition play out in the pharma industry?
A: Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals
Our focus is on completing the LibiGel Phase III clinical work and submitting an NDA in 2012. Our LibiGel partnering strategy from the beginning has been and remains to develop LibiGel as far as we can since we believe the best way to maximize our stockholder value is to bring LibiGel to the latest stage of product development and regulatory status possible. Although we would entertain a license/partnership at this time, we believe the value of LibiGel will increase as new efficacy and safety data become available and these data will be available beginning in the coming months.
Q: Investorideas.com
With other players abandoning the female sexual dysfunction market, your company stayed through the long process and is now postured to be first to market. How significant is it that you have no current competition?
A: Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals
As stated before we believe the market for female sexual dysfunction is significant and we would welcome other companies to develop product for this market. Having said that, today LibiGel is the only product in Phase III clinical development in the world. Assuming positive safety and efficacy data, we believe LibiGel will be the first product approved by the FDA for the treatment of female sexual dysfunction, specifically hypoactive sexual desire disorder. In our primary market research with prescribing physicians, they tell us that there is a great need for an FDA-approved product and that they are dissatisfied with their choices for off-label use. If and when LibiGel is approved we believe it will be a very successful product and result in a very attractive choice for prescribers and women in need, and continued increasing value for our stockholders.
About LibiGel ®
LibiGel is a testosterone gel in Phase III clinical development for the treatment of women who suffer from female sexual dysfunction (FSD). The on-going Phase III efficacy trials are double-blind, placebo-controlled trials that have enrolled over 500 surgically menopausal women each for a six-month clinical trial. The efficacy trials, which have completed enrollment, are being conducted under an FDA-approved special protocol assessment (SPA) agreement. LibiGel is absorbed quickly through the skin after applying a once-daily pea-sized topical application on the upper arm that delivers testosterone to the bloodstream evenly over time.
In a Phase II trial, LibiGel significantly increased the number of satisfying sexual events in surgically menopausal women suffering from FSD by 238 percent versus baseline (p<0.0001); this increase also was significant versus placebo (p<0.05). In this study, the effective dose of LibiGel produced testosterone blood levels within the normal range for pre-menopausal women and had a safety profile similar to that observed in the placebo group. In addition, no serious adverse events and no discontinuations due to adverse events occurred in any subject receiving LibiGel. The Phase II clinical trial was a double-blind, placebo-controlled trial, conducted in the United States, in surgically menopausal women distressed by their low sexual desire and activity.
In addition, BioSante is conducting the Phase III LibiGel safety study, a randomized, double-blind, placebo-controlled, multi-center, cardiovascular (CV) events and breast cancer study that has completed enrollment of 3,656 women and has accrued 4,000 women-years of exposure. The study will continue for a total of five years, however, BioSante will use the safety study data as part of an NDA submission after the last subject enrolled has completed 12 months of exposure to LibiGel or placebo.
The LibiGel safety study is tracking a predefined list of CV events, in agreement with the FDA, including CV death, myocardial infarction and stroke in women 50 years of age or older and suffering from at least two CV risk factors including hypertension and diabetes. The objective of the safety study is to show the relative safety of testosterone compared to placebo in the number of CV events. The incidence of breast cancer also is being tracked over the course of the study. The study represents the largest data base of the safety of testosterone in women.
Upon completion of the statistical analyses of the safety study and efficacy trials, BioSante intends to submit an NDA to the FDA, requesting approval to market LibiGel for the treatment of HSDD in menopausal women. The NDA submission is targeted for the second half of 2012.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel ® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment (SPA). BioSante's first FDA-approved product is Elestrin™ (estradiol gel) indicated for the treatment of hot flashes associated with menopause, marketed in the U.S. by Azur Pharma, BioSante's licensee. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other BioSante products are Bio-T-Gel™, a testosterone gel for male hypogonadism, for which an NDA is pending, licensed to Teva Pharmaceuticals, and an oral contraceptive in Phase II clinical development using BioSante patented technology. Additional information is available online at: www.biosantepharma.com.
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products, the timing of anticipated regulatory submissions and other statements identified by words such as “will,” “continue,” “could,” “believe,” “intends,” “continue,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning, derivations of such words or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly report on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
For Media:
McKinney/Chicago
Alan Zachary
(312) 506-5220
azachary@mckinneychicago.com
BioSante Pharmaceuticals, Inc: (NASDAQ: BPAX) is a featured showcase biotech/pharma stock on Investorideas.com
Request news, updates and trading alerts on BPAX and other showcase stocks http://www.investorideas.com/Resources/Newsletter.asp
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including biotech and pharma stocks.
Disclaimer: The following news/content is paid for as part of the BPAX showcase program (two thousand per month) Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Source: Investorideas.com, BioSante, Investorideas.com
800 665 0411 cvanzant@investorideas.com
Point Roberts, WA, LINCOLNSHIRE, Ill – July 15, 2011 –(Investorideas.com newswire.com) Investorideas.com, an investor research portal covering leading sectors including biotech and pharma stocks, features an exclusive Q&A interview with Mr. Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals, as industry buzz builds on talk of partners or acquisition with value up to $1 Billion.
As BioSante's lead product LibiGel ® (transdermal testosterone gel), for the treatment of female sexual dysfunction gets closer to market, the company is now on the radar as a biotech company to watch.
BioSante Pharmaceuticals Interview
Q: Investorideas.com
Stephen, there is an old saying in the market, that the trading tells the story. The activity and interest in your stock is building from both analysts and retail investors. Can you give us some insight to the key points of the recent analyst coverage and what the industry is saying about your company?
A: Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals
We have been in development of LibiGel for quite a number of years. Finally the finish line is in site. We have completed enrollment of women into our three LibiGel Phase III clinical studies and efficacy data should be available in the fourth quarter of this year. Safety data should be available in the third quarter of 2012 and our objective is to submit the LibiGel new drug application (NDA) to the FDA in the fourth quarter of 2012. All of these dates are near-term opportunities in the biotech/pharma world. Analysts and investors are taking note of the progress we have made with LibiGel.
Q: Investorideas.com
Can you discuss the potential dollar value for a female sexual dysfunction drug hitting the market?
A: Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals
We believe the market for a drug for female sexual dysfunction is potentially bigger than the market for erectile dysfunction drugs, a $2 billion market if the U.S., and male testosterone, a $1.3 billion market in the U.S. Our belief is based on current off-label use of products to treat female sexual dysfunction as well as publications that indicate the potential size of the market for treatment of female sexual dysfunction. It has been over 13 years since Viagra was approved and we believe strongly that women deserve an FDA-approved therapeutic choice for their sexual health issues.
Q: Investorideas.com
With LibiGel ® getting closer to market, how will the process of potential partners or acquisition play out in the pharma industry?
A: Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals
Our focus is on completing the LibiGel Phase III clinical work and submitting an NDA in 2012. Our LibiGel partnering strategy from the beginning has been and remains to develop LibiGel as far as we can since we believe the best way to maximize our stockholder value is to bring LibiGel to the latest stage of product development and regulatory status possible. Although we would entertain a license/partnership at this time, we believe the value of LibiGel will increase as new efficacy and safety data become available and these data will be available beginning in the coming months.
Q: Investorideas.com
With other players abandoning the female sexual dysfunction market, your company stayed through the long process and is now postured to be first to market. How significant is it that you have no current competition?
A: Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals
As stated before we believe the market for female sexual dysfunction is significant and we would welcome other companies to develop product for this market. Having said that, today LibiGel is the only product in Phase III clinical development in the world. Assuming positive safety and efficacy data, we believe LibiGel will be the first product approved by the FDA for the treatment of female sexual dysfunction, specifically hypoactive sexual desire disorder. In our primary market research with prescribing physicians, they tell us that there is a great need for an FDA-approved product and that they are dissatisfied with their choices for off-label use. If and when LibiGel is approved we believe it will be a very successful product and result in a very attractive choice for prescribers and women in need, and continued increasing value for our stockholders.
About LibiGel ®
LibiGel is a testosterone gel in Phase III clinical development for the treatment of women who suffer from female sexual dysfunction (FSD). The on-going Phase III efficacy trials are double-blind, placebo-controlled trials that have enrolled over 500 surgically menopausal women each for a six-month clinical trial. The efficacy trials, which have completed enrollment, are being conducted under an FDA-approved special protocol assessment (SPA) agreement. LibiGel is absorbed quickly through the skin after applying a once-daily pea-sized topical application on the upper arm that delivers testosterone to the bloodstream evenly over time.
In a Phase II trial, LibiGel significantly increased the number of satisfying sexual events in surgically menopausal women suffering from FSD by 238 percent versus baseline (p<0.0001); this increase also was significant versus placebo (p<0.05). In this study, the effective dose of LibiGel produced testosterone blood levels within the normal range for pre-menopausal women and had a safety profile similar to that observed in the placebo group. In addition, no serious adverse events and no discontinuations due to adverse events occurred in any subject receiving LibiGel. The Phase II clinical trial was a double-blind, placebo-controlled trial, conducted in the United States, in surgically menopausal women distressed by their low sexual desire and activity.
In addition, BioSante is conducting the Phase III LibiGel safety study, a randomized, double-blind, placebo-controlled, multi-center, cardiovascular (CV) events and breast cancer study that has completed enrollment of 3,656 women and has accrued 4,000 women-years of exposure. The study will continue for a total of five years, however, BioSante will use the safety study data as part of an NDA submission after the last subject enrolled has completed 12 months of exposure to LibiGel or placebo.
The LibiGel safety study is tracking a predefined list of CV events, in agreement with the FDA, including CV death, myocardial infarction and stroke in women 50 years of age or older and suffering from at least two CV risk factors including hypertension and diabetes. The objective of the safety study is to show the relative safety of testosterone compared to placebo in the number of CV events. The incidence of breast cancer also is being tracked over the course of the study. The study represents the largest data base of the safety of testosterone in women.
Upon completion of the statistical analyses of the safety study and efficacy trials, BioSante intends to submit an NDA to the FDA, requesting approval to market LibiGel for the treatment of HSDD in menopausal women. The NDA submission is targeted for the second half of 2012.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel ® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment (SPA). BioSante's first FDA-approved product is Elestrin™ (estradiol gel) indicated for the treatment of hot flashes associated with menopause, marketed in the U.S. by Azur Pharma, BioSante's licensee. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other BioSante products are Bio-T-Gel™, a testosterone gel for male hypogonadism, for which an NDA is pending, licensed to Teva Pharmaceuticals, and an oral contraceptive in Phase II clinical development using BioSante patented technology. Additional information is available online at: www.biosantepharma.com.
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products, the timing of anticipated regulatory submissions and other statements identified by words such as “will,” “continue,” “could,” “believe,” “intends,” “continue,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning, derivations of such words or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly report on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
For Media:
McKinney/Chicago
Alan Zachary
(312) 506-5220
azachary@mckinneychicago.com
BioSante Pharmaceuticals, Inc: (NASDAQ: BPAX) is a featured showcase biotech/pharma stock on Investorideas.com
Request news, updates and trading alerts on BPAX and other showcase stocks http://www.investorideas.com/Resources/Newsletter.asp
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including biotech and pharma stocks.
Disclaimer: The following news/content is paid for as part of the BPAX showcase program (two thousand per month) Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Source: Investorideas.com, BioSante, Investorideas.com
800 665 0411 cvanzant@investorideas.com
POINT ROBERTS - July 15, 2011 - www.InvestorIdeas.com, a global investor research portal for independent investors, reports on top percentage gainers on the NASDAQ for July 14, 2011. Omega Navigation Enterprises, Inc topped the gainer list, rising about 46% on Thursday.
Omega Navigation Enterprises, Inc. (NASDAQ:ONAV) was the biggest gaineron Nasdaq and soared 0.135 (45.81%) to $0.43 following it announced that, in connection with its Chapter 11 proceedings in Houston, Texas, the Court has granted all of the interim relief that Omega requested.
Icagen, Inc. (NASDAQ:ICGN) also rose 1.85 (30.58%) to $7.90 on no news. The stock also made a new 52-week high of $8.20 on Thursday with more than 5.50 million shares compared to its average volume of 490K shares. The company has a market capitalization of $59.24 million.
Universal Forest Products, Inc. (NASDAQ:UFPI) climbed 5.06 (21.02%) to $29.13 after the company said that its revenue during the second quarter 2011 fell 14.80% year over year to $544.1 million. The company said it won’t resume giving forecasts because of challenging economic conditions. Analysts were estimating the company to report revenue of $564 million.
Gulf Resources, Inc. (NASDAQ:GURE) surged 0.42 (13.00%) to $3.65 it announced that its Chairman, Ming Yang and his family will hold their shares for the next three years and confirmed that Gulf Resources maintains 100% ownership of its two PRC subsidiaries Shouguang City Haoyuan Chemical Ltd. Co. ("SCHC") and Shouguang Yuxin Chemical Industry Co., Ltd. ("SYCI")
Investorideas.com Free Investor Tools;
Sign up for the free investor news and stock alerts in leading sectors! http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas - Research energy stocks, mining, agriculture stocks, cloud computing stocks and more…
Investorideas.com Members currently have 24/7 online access to the exclusive subscriber-only eleven stock directories in leading sectors including renewable
Visit the Investor Ideas membership page to learn more at: http://www.investorideas.com/membership/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising . www.InvestorIdeas.com/About/Disclaimer.asp
For Additional Information and or interest in becoming a content /revenue partner:
Dawn Van Zant: 800-665-0411 - dvanzant@investorideas.com
Source - Investorideas.com
Thursday, July 14, 2011
Iron Ore Stocks Trading Alert; LCY, TRKP, FXPO, FEO
TurkPower Corporation (OTCBB: TRKP) traded up to $0.35 during the day. On Jul 05, 2011, the company announced the purchase of 50.09% working interest in Maksor Madencilik Sanayi Ve Ticaret Anonim Sirketi (hereafter "Maksor"), the 100% private owner of the Kuluncak iron ore project in Turkey.
In a recent Q&A, Ryan E. Hart, Executive Chairman of TurkPower Corporation (OTCBB: TRKP), noted “ With the purchase of controlling interest in the operational Kuluncak iron ore mine, TurkPower is taking its first step toward its goal of becoming a leading junior mining company in Turkey. The purchase adds a tangible and operational asset to the Company's balance sheet and leads to expected profitability in 2011. It also gives the Company leverage and credibility for future mining ventures and acquisitions in the booming mining industry of Turkey.”
Legacy Iron Ore (ASX: LCY) has progressed initial discussions with National Mineral Development Corporation Limited (NMDC), a Government of India state owned public enterprise to meetings in Perth with Legacy.
In June, Legacy defined a maiden JORC compliant Inferred Resource at Mt Bevan Iron Ore project of 617 million tonnes at 32.1% Iron.
Shares of LCY soared 11.70% to $0.105.
FERREXPO (LSE: FXPO.L) closed with a gain of 4.28% to $470.70. Last week, the company said that iron ore production in the second quarter fell 2.5% from the year earlier, taking output for the year down 2.1%.
OCEANIC IRON ORE CORP (TSXV: FEO.V ) gained over 6% to $0.44 after it hosted a total of 9 institutional analysts and shareholders at the Company's inaugural site visit, which took place on July 6 and 7th, 2011.
Iron Ore Stocks Snapshot:
- Cazaly Resources Limited (ASX: CAZ) surged 2.86% to $0.36.
- Eastern Iron Limited (ASX: EFE) ended the day with a gain of 30% at $0.13.
- Mechel OAO (ADR) (NYSE:MTL) jumped 3.84% to $24.62.
- Australasian Resources Ltd. (ASX: ARH) ended the day with a gain of 2.38% to $0.215.
- TurkPower Corporation (OTCBB: TRKP)
TurkPower Corporation (OTCBB:TRKP) is a Turkish-American junior mining company that is acquiring controlling ownership in an operational iron ore mine and several mining projects under development in Turkey. TurkPower's sole focus is on the booming Turkish mining industry, where it aims to become a leader in developing, operating and owning base metal mines by acquiring and consolidating operational mines with proven reserves, utilizing economies of scale to increase returns as well as developing new mining assets. TurkPower's board of
Visit the company profile at Investorideas.com
http://www.investorideas.com/CO/TRKP/
Sign up for news on TRKP and other mining stocks
http://www.investorideas.com/Resources/Newsletter.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sectors. Sectors we cover include; water stocks, gold and mining stocks, China stocks, oil and gas stocks, renewable energy stocks, coal stocks, tech stocks, biotech stocks, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer/ Disclosure: The following news is paid for and /or published as information only for our readers. TRKP is a paid advertising client ( three thousand five hundred per month, 150,000 144 shares) Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of principal .This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
For Additional Information about Investorideas.com energy portals: 800-665-0411 or cvanzant@investorideas.com
Subscribe to:
Posts (Atom)